North Dakota Senate Bill 2370 was signed into law on May 2, 2025, authorizing the Legislative Management to study prescription drug transparency reporting obligations under the federal 340B Drug Pricing Program. The bill requires examination of how covered entities report drug pricing and discount information. The study will be conducted during the 2025-2027 legislative interim with findings to be reported to the 70th Legislative Assembly.

Healthcare providers and pharmaceutical companies participating in the 340B program should be aware that this study may inform future North Dakota legislation on drug pricing transparency. No immediate compliance actions are required; however, stakeholders may consider submitting testimony or public comment during the study process if opportunities arise.